Santhera Revenue Doubles on AGAMREE Momentum, CEO Transition Looms
Event summary
- Santhera Pharmaceuticals revenue grew 97% to CHF 77.2 million in FY2025, significantly exceeding guidance.
- AGAMREE market share reached over 40% in Germany and 50% in Austria, with encouraging early adoption in the UK.
- Santhera secured a USD 215 million licensing agreement with Nxera Pharma for Japan and key Asia-Pacific markets.
- Dario Eklund will step down as CEO on July 15, 2026, and be replaced by Orlando Oliveira.
The big picture
Santhera’s accelerated growth is driven by the increasing adoption of AGAMREE, a rare disease treatment, highlighting the potential of specialty pharmaceuticals in underserved markets. The licensing agreement with Nxera expands Santhera’s reach into the lucrative Asia-Pacific region, but also introduces a new dependency. The CEO transition signals a potential shift in strategy, and investors will be watching closely to see if the new leadership maintains the company’s aggressive expansion plans.
What we're watching
- Leadership Risk
- The success of Santhera’s continued expansion hinges on a smooth handover from Dario Eklund to Orlando Oliveira, and the new CEO’s ability to maintain momentum.
- Partner Performance
- Catalyst’s and Sperogenix’s ability to continue driving AGAMREE sales will be crucial for Santhera’s revenue projections, especially as Catalyst transitions to direct sourcing.
- Reimbursement
- The pace at which Santhera secures reimbursement in additional European markets will dictate the speed of AGAMREE’s broader adoption and revenue growth.
Related topics